Veraxa Biotech Allocates Majority R&D Budget to BiTAC Program Targeting 2028 Milestone
ADCT•Veraxa Biotech said BiTAC molecules will be its main value drivers and will receive the bulk of R&D investment to have a BiTAC-T cell engager candidate by early 2028. The company plans to monetize non-BiTAC assets to finance growth while keeping pipeline development aligned with its partnering strategy.
1. BiTAC Focus and Development Timeline
Veraxa Biotech has declared BiTAC molecules as its primary value drivers, shifting the majority of R&D investment toward this platform. The company aims to advance its first BiTAC-T cell engager candidate into development by early 2028, reflecting a clear timeline for its lead oncology program.
2. Pipeline Progress and Partnering Strategy
In its half-year update, Veraxa reports that pipeline milestones are on track and that high industry interest in T cell engagers has bolstered ongoing discussions. The firm used the recent partnering conference to initiate new collaborations and deepen ties with potential pharmaceutical partners.
3. Financing through Asset Monetization
To support its intensified BiTAC focus, Veraxa plans to monetize selected non-BiTAC assets in the near term. This approach is designed to generate capital for continued R&D spend without diluting equity or increasing debt levels.
